MedTrace Logo

DISsection RE-entry Evaluation With Absorb Bioresorbable Vascular Scaffolds in CTO.

NCT02936011 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-10-18

No results posted yet for this study

Summary

Percutaneous Coronary Intervention (PCI) is increasingly effective to treat Chronic Total Occlusion (CTO) lesions in coronary arteries. This trial will examine modern dissection and re-entry approaches to treat more complex CTO lesions with the Absorb Bioresorbable Vascular Scaffold (BVS).

Conditions

Interventions

DEVICE

CTO PCI using Absorb Bioresorbable Vascular Scaffolds

CTO PCI

Sponsors & Collaborators

  • Bristol Royal Infirmary

    collaborator UNKNOWN

  • Golden Jubilee National Hospital

    collaborator OTHER_GOV

  • Royal Infirmary of Edinburgh

    collaborator OTHER

  • Belfast Health and Social Care Trust

    lead OTHER

Principal Investigators

  • Simon J Walsh, MD · Belfast Health and Social Care Trust

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-03-31
Completion
2019-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02936011 on ClinicalTrials.gov